Tanabe and Taisho Get Big in Japan

Two of Japan's largest pharmaceutical companies, Tanabe Seiyaku and Taisho Pharmaceutical, are merging in response to hard times in the Japanese pharma industry. Their union, which will take at least a year to complete, will create a combined company with $4.3 billion in sales, ranking it third in Japan in revenues. The move won't solve both companies' weak pipeline problems, but it will increase their total R&D budget and give them more sales clout in the domestic market. And as many Japanese pharma companies struggle for survival, analysts believe more merger activity is inevitable.

Tanabe Seiyaku Co. Ltd. 's planned merger with Japan's largest OTC player Taisho Pharmaceutical Co. Ltd. is yet more evidence—should anyone need it—of hard times in the Japanese pharmaceutical industry. A weak economy, increasing pressure on already falling drug prices, historically low R&D investment, and growing competition from foreign companies have left many Japanese players—for the most part highly dependent on the domestic market—struggling for survival. Despite cultural resistance to consolidation of any kind, local companies have no choice but to join forces. In March Mitsubishi Chemical Corp. 's Mitsubishi Tokyo Pharmaceuticals Inc. and Welfide Corp. agreed to merge and most analysts believe there will be more such activity to come.

Tanabe is Japan's tenth largest pharmaceutical company with 2001 sales of $1.5 billion. The mainstay of its business, accounting for...

More from Global Vision

More from In Vivo